JP7734917B2 - トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法 - Google Patents

トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法

Info

Publication number
JP7734917B2
JP7734917B2 JP2021543502A JP2021543502A JP7734917B2 JP 7734917 B2 JP7734917 B2 JP 7734917B2 JP 2021543502 A JP2021543502 A JP 2021543502A JP 2021543502 A JP2021543502 A JP 2021543502A JP 7734917 B2 JP7734917 B2 JP 7734917B2
Authority
JP
Japan
Prior art keywords
cycloalkyl
disease
mitochondrial
trans
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021543502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523702A (ja
JP2022523702A5 (enExample
Inventor
ツー， エムディー， ジェラルド ダブリュー． ドーン，
Original Assignee
ミトコンドリア エモーション， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミトコンドリア エモーション， インク． filed Critical ミトコンドリア エモーション， インク．
Publication of JP2022523702A publication Critical patent/JP2022523702A/ja
Publication of JP2022523702A5 publication Critical patent/JP2022523702A5/ja
Application granted granted Critical
Publication of JP7734917B2 publication Critical patent/JP7734917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021543502A 2019-01-28 2020-01-23 トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法 Active JP7734917B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962797513P 2019-01-28 2019-01-28
US62/797,513 2019-01-28
US201962949060P 2019-12-17 2019-12-17
US62/949,060 2019-12-17
PCT/US2020/014784 WO2020159797A1 (en) 2019-01-28 2020-01-23 Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022523702A JP2022523702A (ja) 2022-04-26
JP2022523702A5 JP2022523702A5 (enExample) 2023-06-05
JP7734917B2 true JP7734917B2 (ja) 2025-09-08

Family

ID=71841885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543502A Active JP7734917B2 (ja) 2019-01-28 2020-01-23 トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法

Country Status (6)

Country Link
US (3) US11083699B2 (enExample)
EP (1) EP3917509A4 (enExample)
JP (1) JP7734917B2 (enExample)
AU (1) AU2020215510B2 (enExample)
CA (1) CA3127453A1 (enExample)
WO (1) WO2020159797A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200323A1 (en) * 2017-04-23 2018-11-01 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
JP7734917B2 (ja) * 2019-01-28 2025-09-08 ミトコンドリア エモーション， インク． トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
KR20230159470A (ko) * 2021-03-19 2023-11-21 미토콘드리아 이모션, 인크. N-(트랜스-4-하이드록시시클로헥실)-6-페닐헥산아미드 및 관련 화합물의 시클로프로판 유사체
WO2022204125A1 (en) 2021-03-22 2022-09-29 Mitochondria Emotion, Inc. Polymorphic forms of n-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide
US20250091983A1 (en) 2021-08-03 2025-03-20 Mitochondria Emotion, Inc. Cyclopentane and cyclohexane variants of 6-phenylhexanamide mitofusin activators and methods for use thereof
WO2024211432A1 (en) * 2023-04-03 2024-10-10 Mitochondria In Motion, Inc. N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide derivatives and related uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073183A1 (ja) 2004-01-28 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. アリールスルフィド誘導体
JP2006511528A (ja) 2002-12-17 2006-04-06 ファイザー株式会社 Ｎｒ２ｂレセプターアンタゴニストとしての２−ピリジル及び２−ピリミジルシクロアルキレンアミド化合物
US20110046128A1 (en) 2008-03-19 2011-02-24 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
WO2015142001A2 (ko) 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2018200323A1 (en) 2017-04-23 2018-11-01 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
JP2022518632A (ja) 2019-01-28 2022-03-15 ミトコンドリア エモーション， インク． マイトフュージン活性化物質及びその使用方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466977A (en) 1981-04-09 1984-08-21 The Upjohn Company N-[2-Amino(oxy- or thia- group-substituted-cycloaliphatic)]benzeneacetamides and -benzamide analgesics
US4438130A (en) 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
US4463013A (en) 1982-04-09 1984-07-31 The Upjohn Company Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4588591A (en) 1984-05-25 1986-05-13 The Upjohn Company Analgesic 2-oxa-spirocyclic compounds
US4632935A (en) 1984-05-30 1986-12-30 The Upjohn Company Omega-(hydroxy-, ether and ester)-alkyl-2-amino-cycloalkyl- and cycloalkenyl amides as analgesics
US4618621A (en) 1984-09-21 1986-10-21 The Upjohn Company Method for treating medical conditions involving cerebral ischemia
US4677122A (en) 1984-11-13 1987-06-30 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4737493A (en) 1985-07-01 1988-04-12 Warner-Lambert Company 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro(4,5)decanes as analgesic agents
US4801604A (en) 1985-10-25 1989-01-31 The Upjohn Company Cis-N-(2-aminocycloaliphatic)benzamide anti-convulsants
US4855316A (en) 1988-02-18 1989-08-08 Warner-Lambert Company 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds
US5051428A (en) 1988-12-06 1991-09-24 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
US5063242A (en) 1989-04-21 1991-11-05 Warner-Lambert Company 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino-1-oxaspiro[4,5]decanes as diuretics antiinflammatory, and cerebrovascular agents
US5366987A (en) 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
MX9706394A (es) * 1995-02-22 1997-11-29 Novartis Ag Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1.
FR2734815B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes arylalkyl (thio) carboxamides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US6127159A (en) 1997-06-06 2000-10-03 The Board Of Trustees Of The Leland Stanford Junior University Mitofusin genes and their uses
AU8003400A (en) 1999-10-06 2001-05-10 Ansgar H. Santel Mitofusins, fzo homologs and functional derivatives thereof
JP4675330B2 (ja) 2003-11-14 2011-04-20 デューク ユニバーシティ シャルコー・マリー・ツース病２ａ型の検出方法
JP2008517072A (ja) 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤
US8354094B1 (en) 2005-01-04 2013-01-15 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8361439B1 (en) 2005-01-04 2013-01-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8791069B1 (en) 2005-01-04 2014-07-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8226928B1 (en) 2011-06-17 2012-07-24 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8574544B1 (en) 2005-01-04 2013-11-05 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US20100047177A1 (en) 2007-01-26 2010-02-25 Washington University Methods and compositions for treating neuropathies
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
WO2009114700A2 (en) 2008-03-12 2009-09-17 The Trustees Of Columbia University In The City Of New York Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion
US20110256565A1 (en) 2008-05-30 2011-10-20 Schon Eric A Methods for diagnosis and treatment of neurodegenerative diseases or disorders
US20110275670A1 (en) 2008-06-04 2011-11-10 Emma Chapman New Compounds VII
WO2011053825A2 (en) 2009-10-30 2011-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment or prevention of mitochondrial diseases
WO2011133879A2 (en) 2010-04-22 2011-10-27 University Of Massachusetts Combination therapies with mitochondrial-targeted anti-tumor agents
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
PH12022550598A1 (en) 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
WO2012158624A2 (en) 2011-05-13 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of mitochondrial fission and methods of use thereof
WO2013010003A1 (en) 2011-07-12 2013-01-17 University Of Medicine And Dentistry Of New Jersey Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
WO2013123305A1 (en) 2012-02-16 2013-08-22 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
HRP20170532T4 (hr) 2012-07-12 2019-12-27 Khondrion Ip B.V. Derivati kromanila za liječenje mitohondrijske bolesti
US20160030517A1 (en) 2012-10-10 2016-02-04 University Of Washington Through Its Center For Commercialization Compositions and methods for diagnosis and treatment of neurological disease
US9603890B2 (en) 2012-12-03 2017-03-28 Vascular Biosciences Methods for increasing the selective efficacy of gene therapy using CAR peptide and heparan-sulfate mediated macropinocytosis
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
EP3043810B1 (en) 2013-09-09 2019-10-23 CanImGuide Therapeutics AB Immune system modulators
US20150168379A1 (en) 2013-12-12 2015-06-18 Macau University Of Science And Technology Method of identifying and screening drug candidate for preventing and/or treating ischemic myocardial disease
CN106061497A (zh) 2013-12-20 2016-10-26 曼尼托巴大学 用于治疗周围神经病变的方法和组合物
EP3108257B1 (en) 2014-02-17 2019-10-30 Société des Produits Nestlé S.A. Methods and uses of mitofusins
JP6659571B2 (ja) 2014-04-16 2020-03-04 ノーザン・シドニー・ローカル・ヘルス・ディストリクト 神経変性障害の治療又は予防のための細胞内Ｎｉｘ介在性マイトファジーを増大させる剤及び方法並びにキット
US10059748B2 (en) 2014-06-10 2018-08-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
US20180085391A1 (en) 2014-08-08 2018-03-29 Modernatx, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
CA2958585C (en) 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
WO2016054083A1 (en) 2014-09-30 2016-04-07 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treatment of amyotrophic lateral sclerosis
US9865522B2 (en) 2014-11-18 2018-01-09 International Business Machines Corporation Composite heat sink structures
KR101647030B1 (ko) 2014-11-20 2016-08-09 한국생명공학연구원 미토푸신 억제제를 포함하는, 세포 리프로그래밍 촉진용 조성물 및 이의 용도
WO2016115632A1 (en) 2015-01-21 2016-07-28 Exerkine Corporation Method for treating mitochondrial disease
WO2016126707A1 (en) 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
US10143719B2 (en) 2015-02-06 2018-12-04 Case Western Reserve University Inhibitors of valosin-containing protein and methods of use
WO2016161294A1 (en) 2015-04-02 2016-10-06 Salk Institute For Biological Studies Err alpha and err gamma are essential coordinators of cardiac metabolism and function
WO2016205193A1 (en) 2015-06-15 2016-12-22 Rush Unversity Medical Center BRAIN DERIVED PPARα LIGANDS
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
CN108476164B (zh) 2015-12-21 2021-10-08 谷歌有限责任公司 在消息传送应用中自动地提供机器人服务的方法
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
WO2018013811A1 (en) 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
US11401255B2 (en) 2016-07-28 2022-08-02 Mayo Foundation For Medical Education And Research Small molecule activators of Parkin enzyme function
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
KR101872105B1 (ko) 2016-09-05 2018-06-27 사회복지법인 삼성생명공익재단 샤르코 마리 투스병 치료용 약학 조성물
WO2018057648A1 (en) 2016-09-20 2018-03-29 The Board Of Trustees Of The Leland Stanford Junior University Peptide regulators of mitochondrial fusion and methods of use
WO2018098484A1 (en) 2016-11-28 2018-05-31 Texas Tech University System Drug targets of delayed aging and human brain diseases
EP3548039B1 (en) 2016-12-04 2023-07-19 Alavi Khorassani Moghadam, Marcel Victor Ribavirin for use in the treatment of a mitochondrial disease
CN120136858A (zh) 2017-03-31 2025-06-13 中美博瑞纳制药有限公司 可用作alcat1抑制剂的化合物
US20200054718A1 (en) 2017-04-05 2020-02-20 Lara S Milane EGFR/MFN2 Targeted Nanoparticles Particularly Useful For Treating Multidrug Resistant Triple Negative Breast Cancer Through Mitochondrial Fusion Inhibition
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
US20210128596A1 (en) 2017-09-27 2021-05-06 University Of Pennsylvania Compositions and methods for treating septic cardiomyopathy
EP3692169B1 (en) 2017-10-06 2023-08-16 Universiteit Antwerpen Biomarkers for charcot-marie-tooth type 2 disease
WO2019079243A1 (en) 2017-10-17 2019-04-25 Albert Einstein College Of Medicine, Inc. MITOFUSIN ACTIVATORS AND USES THEREOF
US10660873B2 (en) 2018-02-23 2020-05-26 University Of South Florida ALDA-1 treatment and prevention of pulmonary disease
CA3097840A1 (en) 2018-04-20 2019-10-24 Fondazione Telethon Mir-181 inhibitors and uses thereof
EP3575401A1 (en) 2018-05-29 2019-12-04 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of treating or preventing an aging-related disease
EP3801515B1 (en) 2018-06-06 2025-04-09 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
WO2020112565A1 (en) 2018-11-29 2020-06-04 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of mitofusion 1 and beta ii pkc association for treating heart failure
JP7734917B2 (ja) * 2019-01-28 2025-09-08 ミトコンドリア エモーション， インク． トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511528A (ja) 2002-12-17 2006-04-06 ファイザー株式会社 Ｎｒ２ｂレセプターアンタゴニストとしての２−ピリジル及び２−ピリミジルシクロアルキレンアミド化合物
WO2005073183A1 (ja) 2004-01-28 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. アリールスルフィド誘導体
US20110046128A1 (en) 2008-03-19 2011-02-24 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
WO2015142001A2 (ko) 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2018200323A1 (en) 2017-04-23 2018-11-01 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
JP2022518632A (ja) 2019-01-28 2022-03-15 ミトコンドリア エモーション， インク． マイトフュージン活性化物質及びその使用方法
JP7473565B2 (ja) 2019-01-28 2024-04-23 ミトコンドリア エモーション， インク． マイトフュージン活性化物質及びその使用方法

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
Langmuir，2013年，29(32)，p.10254-10263
PubChem CID 43476810，2009年07月21日
RN 1212099-39-2 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2010年03月21日，検索日：30 NOV 2023
RN 1212436-66-2, 1212149-30-8, 1212099-39-2, 1212097-75-0 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2010年03月21日，検索日：30 NOV 2023
RN 1214630-71-3, 1214625-16-7 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2010年03月25日，検索日：30 NOV 2023
RN 1309323-83-8 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2011年06月14日，検索日：30 NOV 2023
RN 1350983-54-8 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2011年12月16日，検索日：30 NOV 2023
RN 1787767-39-8 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2015年06月24日，検索日：30 NOV 2023
RN 1901827-77-7 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月02日，検索日：30 NOV 2023
RN 1911441-65-0, 1911441-37-6 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月16日，検索日：30 NOV 2023
RN 1914008-00-6, 1914007-24-1 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月19日，検索日：30 NOV 2023
RN 1914804-74-2, 1914803-34-1 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月20日，検索日：30 NOV 2023
RN 1915622-91-1, 1915622-43-3 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月22日，検索日：30 NOV 2023
RN 1915625-25-0 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月22日，検索日：30 NOV 2023
RN 1916470-29-5 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月23日，検索日：30 NOV 2023
RN 1916478-06-2, 1916477-99-0, 1916477-01-4, 1916467-94-1 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月23日，検索日：30 NOV 2023
RN 1916623-06-7 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月24日，検索日：30 NOV 2023
RN 1919261-32-7, 1919261-11-2, 1919261-05-4 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月27日，検索日：30 NOV 2023
RN 1920519-59-0 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2016年05月29日，検索日：30 NOV 2023
RN 2061612-81-3 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2017年01月30日，検索日：30 NOV 2023
RN 2108235-83-0 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2017年08月04日，検索日：30 NOV 2023
RN 2177990-17-7 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2018年02月21日，検索日：30 NOV 2023
RN 2177990-40-6, 2177990-33-7 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2018年02月21日，検索日：30 NOV 2023
RN 2179442-11-4 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2018年02月26日，検索日：30 NOV 2023
RN 2188823-90-5 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2018年03月11日，検索日：30 NOV 2023
RN 2190211-11-9 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2018年03月13日，検索日：30 NOV 2023
RN 2194323-83-4 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2018年03月19日，検索日：30 NOV 2023
Science，2018年，360(6386)，p.336-341
STN International，file REGISTRY [online]，[令和７年２月１８日検索], 掲載日：～２０１７年２月２０日, CAS Registry No. 2072664-43-6, 2069125-22-8, 1355853-12-1, 1355822-32-0

Also Published As

Publication number Publication date
US20210251925A1 (en) 2021-08-19
EP3917509A4 (en) 2022-11-09
EP3917509A1 (en) 2021-12-08
AU2020215510A1 (en) 2021-07-22
US11083699B2 (en) 2021-08-10
CA3127453A1 (en) 2020-08-06
AU2020215510B2 (en) 2025-03-06
JP2022523702A (ja) 2022-04-26
US20200345668A1 (en) 2020-11-05
US20250099404A1 (en) 2025-03-27
WO2020159797A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
JP7734917B2 (ja) トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
JP7473565B2 (ja) マイトフュージン活性化物質及びその使用方法
US9029367B2 (en) BACE inhibitors
WO2019094830A1 (en) Mitofusin modulation agents and methods of use thereof
CN108463222B (zh) 用于治疗疾病的杂环化合物
JP6526064B2 (ja) ピリドピリミジンジオン誘導体
US20230150990A1 (en) Sphk inhibitors and methods of making and using same
US20240199534A1 (en) Cyclopropane analogues of n-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide and related compounds
US12396968B2 (en) Mitofusin activators having an endocyclic-bonded carbonyl group and methods for use thereof
CN107001240A (zh) 二肽基酮酰胺化合物及其用于治疗和/或预防脂肪积累的用途
EA048983B1 (ru) Циклопропановые аналоги n-(транс-4-гидроксициклогексил)-6-фенилгексанамида и родственных соединений
US20230322667A1 (en) Dihydrofolate synthase (dhfs) inhibiting agents and methods of making and using same
WO2026044165A1 (en) Stereoisomeric fused-cyclopropyl analogues of 4-hydroxycyclohexane carboxamides and related compounds
US20250091983A1 (en) Cyclopentane and cyclohexane variants of 6-phenylhexanamide mitofusin activators and methods for use thereof
US20240034727A1 (en) Imidazole compounds as inhibitors of enpp1

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250819

R150 Certificate of patent or registration of utility model

Ref document number: 7734917

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150